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Summary
 
Cytomegaloviruses encode numerous functions that inhibit antigen presentation in the major
histocompatibility complex (MHC) class I pathway in vitro. One example is the mouse cyto-
megalovirus (MCMV) glycoprotein gp40, encoded by the 
 
m152
 
 gene, which selectively retains
murine but not human MHC class I complexes in the endoplasmic reticulum–Golgi intermediate
compartment/cis-Golgi compartment (Ziegler, H., R. Thäle, P. Lucin, W. Muranyi, T. Flohr,
H. Hengel, H. Farrell, W. Rawlinson, and U.H. Koszinowski. 1997. 
 
Immunity.
 
 6:57–66). To in-
vestigate the in vivo significance of this gene function during MCMV infection of the natural
host, we constructed recombinants of MCMV in which the 
 
m152
 
 gene was deleted, as were the
corresponding virus revertants. We report on the following findings: Deletion of the 
 
m152
 
 gene
has no effect on virus replication in cell culture, whereas after infection of mice, the 
 
m152
 
-defi-
cient virus replicates to significantly lower virus titers. This attenuating effect is lifted by reinsertion
of the gene into the mutant. Mutants and revertants grow to the same titer in animals deprived of
the function targeted by the viral gene function, namely in mice deficient in 
 
b
 
2-microglobulin,
mice deficient in the CD8 molecule, and mice depleted of T cells. Upon adoptive transfer of
naive lymphocytes into infected mice, the absence of the 
 
m152
 
 gene function sensitizes the virus
to primary lymphocyte control. These results prove that MHC-reactive functions protect CMVs
against attack by CD8
 
1
 
 T lymphocytes in vivo.
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T
 
he T cell–mediated immune response is decisive for
control and clearance of most viral infections. CD8
 
1
 
T cells limit virus infections by secretion of cytokines with
antiviral activity and by direct cytolysis of infected cells. To
achieve effective surveillance and elimination of virus-infected
cells, CD8
 
1
 
 T cells need to recognize viral peptides in the
context of MHC class I molecules at the surfaces of infected
cells for maturation to CTLs or for reactivation from mem-
ory (1). Presentation of viral peptides via this pathway re-
quires degradation of viral proteins by the proteasome and
the translocation of the peptides into the endoplasmic retic-
ulum (ER)
 
1
 
 by transporters associated with antigen presen-
tation for loading into the binding groove of nascent MHC
class I molecules and subsequent egress of MHC complexes
to the cell surface (for review see references 2 and 3).
Certain viruses make use of specific and unique genes to
thwart this pathway of virus peptide presentation (for re-
view see reference 4). For example, the adenovirus E3-19K
protein binds and arrests MHC class I molecules in the ER,
and the herpes simplex virus type I–infected cell protein
 
(
 
ICP)47 inhibits transport of peptides into the ER by the
transporters associated with antigen presentation by compet-
ing for the peptide binding site (5–8). Remarkably, CMVs
use multiple genes to interfere with the MHC class I path-
way of antigen presentation. The human (H)CMV encodes
at least four viral polypeptides, each of which can indepen-
dently and by different molecular mechanisms interfere with
MHC class I antigen presentation to inhibit efficient recog-
nition of infected cells by CTLs (9–15). In mouse (M)CMV,
at least three genes affect MHC class I molecules (16, 17, 18).
The function of the viral proteins is usually of selective spec-
ificity for the target proteins of the natural host (16).
Detailed studies of the molecular mechanisms by which
individual viral polypeptides act at various steps of the anti-
gen presentation pathway in vitro are contrasted by the pau-
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city of data concerning the relevance of their function in
vivo. Only the adenovirus E3-19K and herpesvirus ICP47
proteins have been investigated in mice so far (19, 20).
However, mice do not represent the natural host of these
viruses, and, given the species specificity of the functions,
such studies might not completely reflect their physiologi-
cal role for virus control.
Therefore, the question of the biological significance of
the individual viral evasion mechanisms should be addressed
in the natural host of the virus. MCMV offers the unique
opportunity to study the biological impact of herpesviral
immune evasion genes in vivo. Comparable to HCMV,
MCMV already tightly controls the presentation of viral
antigens at early (E) phases of infection (21). The effect is
achieved by blocking transport of MHC class I molecules
to the cell surface (22). We have identified the 
 
m152 
 
gene
responsible for inhibition of MHC class I antigen presenta-
tion in the E phase of virus gene expression. The MCMV E
glycoprotein gp40 encoded by the 
 
m152
 
 gene blocks the
export of MHC class I complexes from the ER/cis-Golgi
compartment and thereby prevents the presentation of viral
peptides to CTLs (16). Similar to HCMV, additional MCMV
functions exist that also control antigen presentation in the
MHC class I pathway (23). Two additional proteins we have
identified are the products of the 
 
m04
 
 and 
 
m06
 
 genes, which
form complexes with MHC class I molecules (17, 18).
Here, we constructed mutants of MCMV that lacked the
 
m152
 
 gene as well as the corresponding virus revertants. We
investigated the susceptibility of these recombinant viruses
to host immune control. We demonstrate that the deletion
of the 
 
m152
 
 gene results in high susceptibility of the virus
to CD8 T cell control. We conclude that even the deletion
of a single viral gene from a group of genes that interfere
with the MHC class I presentation pathway affects the fitness
of CMV in vivo.
 
Materials and Methods
 
Cells and Viruses.
 
Mouse NIH 3T3 cells (American Type Culture
Collection [ATCC] CRL1658) were grown in DME supplemented
with 10% newborn calf serum. Primary mouse embryonic fibro-
blasts (MEFs) prepared from BALB/cJ mice and B12 cells (24) were
grown in MEM with 10% FCS. The Smith strain of MCMV
(VR-194; ATCC) and the recombinant viruses were propagated on
third-passage MEFs and purified by sucrose gradient centrifugation.
Tissue culture–grown virus preparations were used throughout.
 
Construction of Recombination Plasmids and Recombinant Viruses.
 
Plasmid constructions were performed by standard methods (25).
Plasmid p152KO used for generating 
 
m152
 
2
 
 recombinant viruses
was constructed by ligation of a 5-kb NotI–BamHI fragment
comprising a 
 
loxP
 
-flanked 
 
lacZ
 
 cassette (26) into the XhoI/NheI-
digested plasmid pEcoO
 
D
 
MB (all sites were blunt-ended by treat-
ment with Klenow DNA polymerase). Plasmid pEcoO
 
D
 
MB con-
tains a 5.0-kb EcoRI–MluI fragment of the MCMV genome
(MCMV nucleotides 209,756–214,714) encompassing the 
 
m152
 
gene (27). To generate recombination plasmid pm152gpt, the 
 
Esch-
erichia coli
 
 
 
gpt
 
 gene was flanked with 
 
loxP
 
 sites and inserted into an
XhoI site of plasmid pEcoO
 
D
 
MB at the 3
 
9
 
 end of the 
 
m152
 
 gene.
Recombinant viruses were generated by homologous recombi-
 
nation in NIH 3T3 as described previously (26). 
 
LacZ
 
1
 
 recombi-
nants were identified by 5-bromo-4-chloro-3-indolyl-
 
b
 
-
 
d
 
-galac-
topyranoside (X-gal) staining and isolated by at least five rounds
of limiting dilution passage. Recombinant viruses carrying the 
 
gpt
 
marker were first enriched by selection in medium that was sup-
plemented with 12.5 
 
m
 
g/ml mycophenolic acid (GIBCO BRL)
and 100 
 
m
 
g/ml xanthine (Sigma Chemical Co.) (28) and further
purified by limiting dilution. 
 
LacZ
 
2
 
 and 
 
gpt
 
2 
 
mutants were gener-
ated by a single passage through the recombinase 
 
Cre
 
1
 
 cell line,
N2 (26). 
 
LacZ
 
2
 
 recombinants were identified as white plaques after
X-gal color screening and purified by limiting dilution. 
 
Gpt
 
2
 
 mu-
tants were selected on STO cells (ATCC CRL-1503) in medium
containing 20 
 
m
 
g/ml 6-thioguanine (Sigma Chemical Co.) as de-
scribed previously (29). To characterize the recombinant virus
genomes, viral DNA was isolated from infected cells and analyzed
by Southern blot analysis (26).
 
Characterization of Viral Proteins.
 
B12 cells were infected with
wild-type MCMV or 
 
m152
 
 recombinant viruses. Cells were pulse
labeled at 37
 
8
 
C for 60 min with 500 
 
m
 
Ci/ml [
 
35
 
S]methionine
(1,200 Ci/mmol; Amersham) in methionine-free MEM supple-
mented with 5% dialysed FCS and chased in the presence of 10
mM nonlabeled methionine for 2 h. Labeled cells were washed
in ice cold PBS and disrupted in lysis buffer (140 mM NaCl, 20
mM Tris/HCl, pH 7.6, 5 mM MgCl
 
2
 
, 1% NP-40, and 1 mM
PMSF). Cytoplasmic extracts were precleared by incubation
with normal mouse serum, antiactin mAb (Boehringer Mann-
heim), and protein A–coupled Sepharose (Pharmacia). Immu-
noprecipitations were performed with anti-K
 
d
 
 mAb MA-215 ascitic
fluid, and immune complexes were retrieved using protein A–cou-
pled Sepharose. Endoglycosidase H (Endo H; Boehringer Mann-
heim) digestion and SDS-PAGE were performed as described pre-
viously (23).
 
Cytolytic Assays.
 
Target cells were labeled for 90 min with
Na
 
2
51
 
CrO
 
4
 
,
 
 
 
and a 4-h standard release assay was performed with 10
 
3
 
target cells and a graded number of effector cells in fivefold dilution
steps as described (21, 30). In short, for selective and enhanced ex-
pression of immediate-early (IE) genes, MEFs were infected with
0.5 PFU of recombinant viruses or wild-type MCMV per cell by
centrifugation (800 
 
g
 
, 30 min). Infection was performed in the pres-
ence of cycloheximide (50 
 
m
 
g/ml), which was removed 3 h later by
washing with medium containing actinomycin D (5 
 
m
 
g/ml). Lim-
ited E gene expression after CH treatment was achieved by removal
of cycloheximide using inhibitor-free medium and by adding actino-
mycin D to the final concentration of 5 
 
m
 
g/ml after 1.5 h. To gen-
erate pp89-specific polyclonal CTLs, MCMV-primed spleen cells
were restimulated with pp89-derived antigenic peptide (21), and re-
combinant IL-2 (100 U/ml) was added 5 d later. Cultures were re-
stimulated with gamma-irradiated syngeneic MEFs pulsed with anti-
genic peptide at a concentration of 10
 
2
 
8
 
 M. Data represent the mean
percentage of specific lysis from three replicate cultures (see Fig. 2 B).
 
Animals and Infection Conditions.
 
BALB/c (H-2
 
d
 
 haplotype) and
C57BL/6 mice (H-2
 
b
 
 haplotype) were bred at the Central Ani-
mal Facilities at the Medical Faculty, University of Rijeka. Mice
homozygous for the 
 
m
 
 chain mutation (C57BL/6 background;
reference 31) were provided by Dr. Klaus Rajewsky (Institute for
Genetics, Cologne, Germany) and were backcrossed on the BALB/c
background for 10 generations. Mice heterozygous (
 
m
 
MT
 
2
 
/
 
1
 
)
and homozygous (
 
m
 
MT
 
2
 
/
 
2
 
) for the 
 
m
 
 chain mutation were dis-
tinguished by ELISA for the presence or absence of IgM in mouse
sera, as described previously (32). Mice homozygous for the 
 
b
 
2 mi-
croglobulin mutation (
 
b
 
2
 
m
 
2
 
/
 
2
 
; supplied by Dr. Rudolf Jaehnisch,
Whitehead Institute of Biomedical Research, Cambridge, MA)
fail to express ternary MHC class I complexes and are devoid of 
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Figure 1. Characterization of
m152 recombinant viruses. (A)
Genome structure of recombi-
nant viruses. The HindIII cleavage
map of the MCMV strain Smith
genome is shown at the top, and
the expanded HindIII E region
of wild-type and recombinant
viruses is shown below, with the
HindIII (H) and EcoRI (E) cleav-
age sites indicated. The open box
with the arrow depicts the posi-
tion and orientation of the m152
gene, and the shaded boxes rep-
resent viral sequences that were
used for homologous recombi-
nation. The positions of the loxP
sites are indicated by asterisks (*).
The marker genes used for selec-
tion, loxZ and gpt, are indicated.
The probe used for Southern
blot analysis is represented by a
bar. The expected sizes of the
HindIII and EcoRI fragments are
indicated by arrows. (B) Southern
blot analysis of the recombinant
virus genomes. DNA was iso-
lated from infected NIH 3T3
cells and digested with restriction
enzymes HindIII and EcoRI,
respectively. Sizes of the DNA
fragments are indicated in kb.
 
CD8
 
1
 
 T lymphocytes (33). Mice homozygous for the deletion
of the gene encoding the CD8 molecule (CD8
 
2
 
/
 
2
 
) were obtained
from the Centre de Developpement des Techniques Avancées
pour l’Expérimentation Animale, Institut de Transgenose, Orleans,
France. The absence of CD8
 
1
 
 T lymphocytes in 
 
b
 
2
 
m
 
2
 
/
 
2
 
 and
CD8
 
2
 
/
 
2
 
 mice was verified by flow cytometry as described previ-
ously (34). Neonatal mice, 24 h and 4 d postpartum, were injected
intraperitoneally with recombinant viruses or wild-type MCMV.
6–8-wk-old mice were injected either in the posterior footpad or
i.p. with 2 
 
3
 
 10
 
5
 
 PFU of virus in a volume of 50 and 500 
 
m
 
l of
diluent, respectively, as described (35).
 
Detection of Infectious MCMV in Tissues and Statistical Evaluation.
 
Plaque assays were performed in MEF as described previously
(36, 37). Statistical significance of differences between the experi-
mental groups was determined by the Mann-Whitney exact rank
sum test. Virus titers (x and y) were considered significantly differ-
ent for
 
 P 
 
(x versus y) 
 
,
 
 alpha 
 
5 
 
0.05 (one sided), where
 
 P is the
observed probability value and alpha is a selected significance level.
In Vivo Depletion of Lymphocyte Subsets. In vivo depletion of
CD41 and CD81 T lymphocyte subsets was performed by intra-
peritoneal injection of mAbs (rat anti–mouse) to CD4 (YTS 191.1)
and/or CD8 (YTS 169.4) molecules (38). Adult and newborn
mice received 1 mg and 250 mg of antilymphocyte antibodies, re-
spectively, at the time of injection and every fifth day throughout
the experiment. The efficacy of T lymphocyte depletion was
.95%, as assessed by cytofluorometric analysis of spleen cells using
FITC- or PE-conjugated antibodies directed against mouse CD4
and CD8 molecules (Becton Dickinson; nos. 1333 and 1447).
Adoptive T Lymphocyte Transfer. Donor T lymphocytes were
harvested from spleens of uninfected (nonprimed) or latently in-
fected (MCMV-primed) mice. Recipient mice were injected
with 2 3 105 PFU of virus in a rear footpad 12 h after gamma ir-
radiation (6.5 Gy). Immediately after infection, 2 3 105 nylon
wool–purified cells were injected intravenously into recipient
mice. Mice that did not receive cell transfer were used as negative
controls. Mice were killed on day 14 after infection, and tissues
were harvested for virus titer determinations.
Results
Generation of Recombinant MCMV. To investigate the sig-
nificance of the m152 gene product in the course of infection,
a targeted deletion of the m152 gene and subsequent reintro-
duction of this gene into the MCMV genome was performed
(Fig. 1 A). The recombinant virus DMC95.21 was generated
by homologous recombination between the wild-type
MCMV genome and the recombination plasmid p152KO.
In this plasmid, a 1.2-kb XhoI–NheI fragment containing the
m152 gene was replaced by a loxP-flanked E. coli lacZ gene.
The lacZ marker was excised by passaging the DMC95.21 re-
combinant through the recombinase Cre1 cell line N2 (26)
to create the m1522lacZ2 deletion mutant DMC95.24. To
generate a revertant virus, the m152 gene, together with the
loxP-flanked gpt gene, was reinserted by homologous re-
combination into the DMC95.21 genome. After positive
selection (28) of the m1521gpt1 virus rMC95.26, the gpt
marker gene was again removed by passaging the virus
through the recombinase Cre1 cell line N2 to generate the
m1521gpt2 revertant virus (designated rMC96.27).
Southern blot analysis of the recombinant virus genomes
confirmed the recombination events at the expected positions
(Fig. 1 B). In the mutant virus genomes, the original 23.3-kb
HindIII E fragment and the 5.9-kb EcoRI O fragment were1288 MCMV Gene m152 Protects against CD8 T Cell Attack In Vivo
replaced by expected new HindIII and EcoRI fragments.
HindIII fragments of 20.0 and 6.5 kb and EcoRI fragments
of 4.8 and 3.5 kb are evident in DMC95.21, whereas in the
m1522lacZ2 deletion mutant, DMC95.24, a 22-kb HindIII
fragment and a 4.7-kb EcoRI fragment were found. In the
genomes of the rMC95.26 and rMC96.27 revertant viruses,
HindIII fragments of 21.2 and 2.9, and 23.2 kb, and EcoRI
fragments of 6.4 and 0.4 kb, and 5.5 and 0.5 kb, were ob-
served, respectively. Note that the size of the HindIII E frag-
ment in the rMC96.27 genome is identical to that in the
wild-type MCMV genome, whereas a new EcoRI site pur-
posely introduced outside of the m152 open reading frame
enabled us to discriminate between the constructed revertant
and wild-type MCMV. Comparison of the HindIII, EcoRI,
and XbaI digestion patterns of the recombinant genomes
with those of the wild-type MCMV genome confirmed that
the recombinant viruses were free of detectable deletions or
insertions in any other region of the viral genome (data not
shown).
Maturation of MHC Class I Molecules in Cells Infected with
the m152 Deletion Mutant. The altered glycosylation pattern
of newly synthesized molecules can be used to locate the
export block of nascent MHC class I molecules in MCMV-
infected cells (1, 22, 23). Correctly assembled MHC class I
complexes retained by the m152 gene product in the
ERGIC/cis-Golgi compartment of MCMV-infected cells
are not processed by medial-Golgi enzymes to complex
glycans. Therefore, the majority of MHC class I molecules
from cells infected with wild-type MCMV exhibit high
mannose N-linked glycans typical for this compartment
that are sensitive to Endo H and migrate faster in gels after
digestion with Endo H (Fig. 2 A). In contrast, MHC class I
complexes in cells infected with the m152 deletion mutant
DMC95.21 as well as in uninfected cells acquire Endo
H–resistant glycans, indicating the normal egress from the
ERGIC/cis-Golgi compartment. As expected, the MHC
class I transport was affected again in cells infected with the
revertant virus rMC96.27, demonstrated by the reappear-
ance of molecules sensitive to Endo H digestion.
Deletion of the m152 Gene Restores Presentation of Viral An-
tigens to CTLs. The transport arrest of MHC class I mole-
cules by the MCMV m152 gene product at early (E) times
of virus replication prevents surface expression of these
molecules and thus the recognition and lysis of infected
cells by specific CTLs (1). A deletion of this gene should
restore the recognition of infected cells by CTLs under the
experimental conditions. To test this, MEFs were infected
with the m152 deletion mutant DMC95.21, the revertant
virus rMC96.27, or wild-type MCMV. Infected cells were
arrested in the IE or E phase of the MCMV replication cycle
and used in a CTL assay with MHC class I–restricted CTLs
specific for the MCMV antigen pp89 (21, 30, 36). As ex-
pected, recognition and cytolysis were equivalent for cells
infected with all three viruses during the IE phase of the vi-
ral replication cycle, a time at which the m152 gene product
is not yet expressed (Fig. 2 B). However, recognition was
impaired during the E phase when cells infected with wild-
type or revertant virus were used as targets. In contrast, ef-
ficient recognition of DMC95.21-infected cells was seen,
confirming that retention of MHC class I molecules and
the associated block in antigen presentation is mediated un-
der these conditions exclusively by the m152 gene.
Replication of m152 Deletion Mutant and Revertant Virus in
Cell Culture. Multistep growth curves of recombinant
Figure 2. Functional characterization of the m152 deletion mutants. (A) Normal maturation of newly synthesized MHC class I molecules in cells in-
fected with the m152 deletion mutant. B12 cells were either mock infected or infected with wild-type MCMV or DMC95.21 and rMC96.27 recombi-
nants. 6 h after infection, cells were pulse labeled for 1 h with [35S]methionine, and newly synthesized molecules were chased for 2 h. Kd MHC class I com-
plexes were precipitated from cell lysates with anti-Kd mAb MA-215. Half of the precipitates were digested with Endo H or mock treated before
separation by 12.5% SDS-PAGE. The different glycosylation forms of the MHC class I heavy chains with regard to Endo H sensitivity are denoted as r,
Endo H resistant; s, Endo H sensitive; or d, Endo H digested. MWM, molecular weight marker. (B) Restoration of MHC class I antigen presentation in
cells infected with the m152 deletion mutant. BALB/c MEFs were infected with wild-type (w.t.) MCMV, the m152 deletion mutant DMC95.21, and
the revertant virus rMC96.27 under conditions that allowed expression of only IE (n) or IE and E viral proteins (d). Antigen presentation was tested
with CTLs specific for the MCMV antigen pp89 at the indicated E/T ratios in a 4-h 51Cr-release assay.1289 Krmpotic et al.
and wild-type viruses served to assess whether the deletion
of the m152 gene affects virus growth in cell culture. After
infection of NIH 3T3 fibroblasts at a multiplicity of infec-
tion of 0.1 PFU per cell, replication of the m152 deletion
mutant and revertant were indistinguishable from that of
MCMV wild-type virus (Fig. 3). Identical results were ob-
tained by comparing the replication capacity of the m152
deletion mutants, the revertant virus, and MCMV wild type
on primary MEFs (not shown), indicating that the m152
gene product is completely dispensable for virus growth in
fibroblasts.
Replication of the m152 Deletion Mutant In Vivo. Consider-
ing the fact that three different MCMV genes affect nascent
MHC molecules and that m152 merely represents the gene
that is expressed first, it was not clear whether or not the
deletion of this gene would have any detectable impact on
the susceptibility of the virus to immune control in vivo.
Whereas adult mice control the infection with tissue cul-
ture–derived wild-type MCMV effectively, young mice al-
low virus replication to high titers (39, 40). To detect even
minor differences in virulence due to deletion of the single
m152 gene, we assayed virus replication in neonatal mice.
To avoid the potential influence of marker gene products
on the biological properties of mutant viruses, the in vivo
experiments were performed mainly with the m152 deletion
mutant DMC95.24 and the revertant virus rMC96.27, al-
though the other mutants gave comparable results (data not
shown). Neonatal mice were injected with 100 PFU of the
m152 deletion mutant, the revertant virus, or wild-type
MCMV and monitored for 30 d. After infection with wild-
type MCMV or revertant virus, 53 and 75%, respectively, of
animals succumbed to infection (Fig. 4 A). In contrast, infec-
tion with the m152 deletion mutant was survived by the ma-
jority of mice (25% mortality). With respect to clinical signs,
all three groups of mice exhibited during the first week of
infection significant runting and a general failure to thrive
compared with mock-infected controls. By 14–20 d after in-
fection, however, most animals that survived the infection
with the m152 deletion mutant had recovered. In contrast,
clinical signs persisted throughout the course of observation
for wild-type MCMV and revertant virus–infected mice.
The different disease courses correlated with the body
weights of infected mice. On day 26 after infection, the av-
Figure 3. In vitro growth of recombinant viruses. NIH 3T3 cells were
infected with wild-type MCMV (s), DMC95.24 (m), or DMC95.21 (d)
recombinants at a multiplicity of infection of 0.1 PFU per cell. Superna-
tants (A) and cells (B) were harvested at the indicated time points after in-
fection (p.i.), and virus titers were determined.
Figure 4. Reduced virulence and replication capacity of the m152 de-
letion mutant in vivo. (A) Newborn BALB/c mice were inoculated with
100 PFU i.p. of wild-type (w.t.) MCMV (s), DMC95.24 (filled gray tri-
angles), or rMC96.27 (d) virus 12 h post partum, and their survival was
monitored daily. (B) Newborn BALB/c mice were infected as shown in
A, and virus titers were determined 8 d after infection. Data represent the
mean value of at least five mice.1290 MCMV Gene m152 Protects against CD8 T Cell Attack In Vivo
erage body weight of mice that survived infection with
DMC95.24 was comparable to that of the control group
(9.79  6  1.86 and 10.9 6 1.16 g, respectively), whereas mice
infected with the revertant virus still appeared runted (7.04 6
1.70 g; data not shown).
To assess whether the differences were due to an altered
tissue tropism associated with the m152 deletion, virus titers
were determined for lungs, spleen (Fig. 4 B), and salivary
glands (data not shown). The mutant DMC95.24 yielded
lower titers in the spleen and lungs as compared with wild-
type MCMV and the revertant virus. Although the differences
in virus titers in tissues of neonatal mice did not exceed 1–2
log10 steps, this finding was reproducible both in MCMV-
sensitive (BALB/c) as well as MCMV-resistant (C57BL/6)
mouse strains. In the salivary glands, this observation could
not be made. In this organ, the virus titer yielded by the
m152 deletion mutant was indistinguishable from that of the
wild-type and revertant virus. In this context, it is of inter-
est to note that we have demonstrated earlier that the salivary
gland represents the only organ in which MCMV replication
is exempt from CD81 T cell control (41). Altogether, the
lack of the m152 gene results in an attenuated course of in-
fection and in restricted virus growth.
The Attenuation of the m152 Deletion Mutant Is a Function of
T Cells. Immunodeficient mice were used to assess whether
the attenuated phenotype of the m152 deletion mutant indeed
reflected an enhanced sensitivity to T cell control. BALB/c
mice were immunodepleted by gamma irradiation and by
injection with cytolytic antibodies to T lymphocytes and NK
cells. In immunodepleted animals, all three viruses replicated
to high titers without significant titer differences (data not
shown). This demonstrated already that the attenuated pheno-
type of the m152 deletion mutant is caused by an increased
sensitivity to immune control mechanisms. The m152 de-
letion mutant replicates to lower virus titers than the rever-
tant virus (Fig. 5 A, left panels; P , 0.005) in undepleted
BALB/c as well as C57BL/6 mice (Fig. 5 A, top and bottom
panels, respectively). This growth restriction was abrogated
after depletion of T lymphocyte subsets (Fig. 5 A, right pan-
els), indicating that the attenuated phenotype of the deletion
mutant is caused by an enhanced sensitivity to T cell control.
B cell–deficient (mMT2/2) mice were employed to iden-
tify the relative role of T cell subsets (Fig. 5 B). Due to the
lack of specific antibodies, MCMV spreads rapidly in
mMT2/2 mice, and detection of infectious virus is facili-
tated (35). 8-wk-old mMT2/2 mice were depleted of only
CD81 T lymphocytes, depleted of both CD81 and CD41
T cell subsets, or left undepleted. Virus titers were deter-
mined 10 d after infection. The growth restriction of the
m152 deletion mutant was notable in particular in the lungs
of nondepleted mice, resulting in titer differences ranging
from 2 to 3 log10 (Fig. 5 B, left panels). After depletion of
CD81 T lymphocytes or of both T cell subsets, mutant and
revertant virus reached comparable virus titers (Fig. 5 B,
center and right panels). These data demonstrate that CD81
T cells are the relevant cell subset responsible for the repli-
cation inhibition associated with the m152 gene deficiency.
Furthermore, the attenuating effect is also seen in adult mice.
Although the differences are not significant, in BALB/c
mMT2/2 mice, the m152 deletion mutant reached slightly
Figure 5. Attenuation of the m152 deletion
mutant is T cell dependent. (A) 4-d-old BALB/c
and C57BL/6 mice were depleted of CD41
and CD81 T lymphocytes or were left un-
treated, and they were then infected with 1,000
PFU i.p. of the DMC95.24 (s) or rMC96.27 vi-
ruses (d). 10 d after infection, virus titers were
determined. Titers of individual mice (circles)
and median values (horizontal bars) are shown.
There was a significant difference in virus titers
between  DMC95.24 and rMC96.27 in both
mouse strains (P , 0.005; left panels). Deple-
tion of T cells abrogated the difference (right
panels). (B) 8-wk-old B cell–deficient mice
(mMT2/2, BALB/c background) were depleted
of CD81 T cells or both CD41 and CD81 T
lymphocytes, or they were left untreated. Mice
were infected with 2 3 105 PFU i.p. of the
DMC95.24 and rMC96.27 viruses, and virus ti-
ters were determined 10 d after infection. Titers
in individual animals and median values (hori-
zontal bars) are shown. The differences in virus
titers between the groups of nondepleted mice
infected with DMC95.24 and rMC96.27 were
significant (P , 0.005) for titers in lungs and
spleens (left panels). Depletion of both T cell
subsets abrogated the differences between the
two recombinants in both organs tested (right
panels). Depletion of only CD81 T cells re-
duced but did not abolish the differences be-
tween the two viruses (P , 0.05; center pan-
els). DL, detection limit.1291 Krmpotic et al.
lower titers than the revertant, even after depletion of T
cell subsets.
No Phenotype of the m152 Deletion Mutant in MHC Class
I–deficient and CD81 T Cell–deficient Mice. The m152 gene
function affects antigen presentation in the MHC class I
pathway. Therefore, in mice in which this presentation
pathway is defective, the specific defect of the virus should
be phenotypically complemented. To test this, we used MHC
class I–deficient C57BL/6 b2m2/2 mice (33) and mice defi-
cient for CD81 T lymphocytes due to the deletion of the
CD8 gene (C57BL/6 CD82/2 mice). 4-d-old mice were in-
fected with 1,000 PFU of either the m152 deletion mutant
or the revertant virus. In contrast to the situation in immu-
nocompetent mice, no difference in the titers between the
two viruses was found in three replicate experiments per-
formed in b2m2/2 and CD82/2 mice. One representative
experiment is shown in Fig. 6. Essentially, the same mes-
sage was obtained in adult CD82/2 mice infected with the
m152 deletion mutant or the revertant virus. However,
adult mice of the C57BL/6 strain cleared both viruses so
efficiently that the titers in tissues were below the threshold
levels when assayed 10 d after infection. Therefore, to en-
hance the virus replication and to get a measurable virus
load in tissues, we had to deplete NK cells in vivo (data not
shown). Altogether, these experiments show that attenua-
tion of the m152 deletion mutant is directly linked to func-
tions required for antigen presentation and recognition in
the MHC class I pathway.
Increased Susceptibility of the m152 Deletion Mutant to Naive
Lymphocytes. Adoptive cell transfer into immunodepleted
recipients was used to determine the sensitivity of MCMV
N2 virus-primed as well as to naive lymphocytes. Lethal
MCMV infection in gamma-irradiated BALB/c mice is
therapeutically prevented by adoptive transfer of as few as
105 MCMV-primed CD81 T cells, whereas the same num-
ber of naive lymphocytes or primed CD41 T cells is inef-
fective (37, 41, 42). As the product of the m152 gene down-
regulates presentation of viral antigens in the MHC class I
pathway, we expected to see an increased sensitivity of the
mutant to primed T cells and perhaps also a more effective
priming of T lymphocytes.
To test this, 2 3 105 lymphocytes derived from BALB/c
mice, either MCMV primed or naive, were intravenously
transferred into syngeneic gamma-irradiated recipients 12 h
after infection with wild-type MCMV, the m152 deletion
mutant, or the revertant virus strain. Adoptive T cell con-
trol of MCMV is a selective function of CD8 T cells but not
of CD4 T cells and is more effective in spleen and liver
than in the lungs (37, 42). Accordingly, the replication of
the m152 deletion mutant is more efficiently controlled in
these organs than the revertant virus.
Small numbers (z105) of naive T lymphocytes fail to
protect mice against MCMV infection (41). This was re-
produced for mice infected with the revertant virus; how-
ever, the number of 2 3 105 naive lymphocytes already
decreased the titers of the m152 deletion mutant (Fig. 7).
This is a function of T lymphocytes, as depletion of the
CD8 T cell subset eliminated this activity (data not shown).
Transfer of graded numbers of naive cells into gamma-irra-
diated mice showed that the number of naive T cells had to
be increased by 100-fold to achieve an effect on wild-type
MCMV comparable to the effect on revertant MCMV
Figure 6. No growth difference of m152 deletion and revertant viruses
in b2m2/2 and CD82/2 mice. Normal C57BL/6, b2m2/2, and CD82/2
mice (all 4 d old) were inoculated with 1,000 PFU i.p. of the DMC95.24
(open bars) or rMC96.27 (shaded bars) recombinant viruses. Shown are
virus titers in lungs 10 d after infection. Data represent the mean value of
five mice. There was a significant difference in virus titers between
DMC95.24 and rMC96.27 viruses (P , 0.005). The titer difference between
the two viruses in b2m2/2 and CD82/2 mice is not significant.
Figure 7. Susceptibility of the m152 deletion mutant to MCMV-
primed and naive T lymphocytes. 8-wk-old BALB/c gamma-irradiated
mice were injected with 105 PFU of DMC95.24 or rMC96.27 virus. 2 3
105 T lymphocytes were obtained from latently infected or uninfected
BALB/c mice, and cells were transferred intravenously into recipients im-
mediately after infection. Mice that did not receive cell transfer were used
as negative controls. Shown are titers in individual recipients, measured
13 d after transfer and infection. Horizontal bars indicate the median val-
ues. DL, detection limit.1292 MCMV Gene m152 Protects against CD8 T Cell Attack In Vivo
(data not shown). We therefore concluded that deletion of
the m152 gene increases the antigenicity of the virus.
Discussion
Herpesvirus genomes contain several genes coding for po-
tential immunomodulatory functions. Shared between vi-
ruses of the a- and the b-herpesvirus family is the expression
of gene functions that interfere with peptide presentation in
the MHC class I pathway in vitro. Herpesviruses are highly
species specific, and so are the functions of the genes that
affect this pathway. No cellular homologue has been detected
for any of these genes so far (4). For a better understanding
of the contribution of each individual gene to the biology
of the virus infection, experiments in the natural host are
required. Here, we report on the in vivo function of the im-
munomodulatory protein encoded by gene m152 of MCMV
during infection of its natural host.
To prove that a gene has a predicted immunoregulatory
function in vivo, three aspects must be addressed. First, the
deletion of the gene from the genome should not affect virus
growth in cells in the absence of immune control. Second,
a phenotype seen in vivo should be lifted by a targeted rever-
tant of the virus. Third, the attenuation due to lack of the
immunomodulatory function of the virus should be phe-
notypically complemented in a host that is genetically or
functionally disabled to exert the control that is specifically
affected by the deleted viral gene product.
Only the fulfillment of all three requirements confirms
the prediction of the in vitro studies. Not all virus genes
that have an effect on specific immune effector mechanisms
in vitro show this effect in vivo as their main function. One
such example is the Fc receptor function encoded by gene
m138 of MCMV. The Fc receptor is expressed at the cell
surface and selectively binds mouse IgG in vitro. The deletion
of m138 results in strong attenuation of the mutant virus in
vivo that is lifted by the specific revertant. However, in Ig-
deficient mice, the attenuation is still present, proving that
attenuation of the virus due to the deletion of the Fc recep-
tor is not linked to Ig control (26, 43).
The m152 gene encodes the glycoprotein gp40, which
arrests the export of nascent mouse but not human MHC
class I molecules (16). If this was the major function of the
protein, then the deletion of the gene should be dispens-
able for virus growth in fibroblasts but should restrict repli-
cation in immunocompetent animals. This prediction was
fulfilled by the m152 deletion mutant viruses. Virus growth
in vivo but not in fibroblasts was affected by the mutation.
Furthermore, the MHC class I complex transport and the
capacity to present viral peptides to CD8 T lymphocytes
was restored.
The revertant virus regained wild-type properties in vivo
and fulfilled the second requirement by proving the causal
linkage between targeted deletion and biological phenotype.
As with HCMV infection in humans, the primary infection
of mice even with wild-type MCMV is usually asympto-
matic. Newborn mice and mice that are a few days old are
much more sensitive than adult mice to tissue culture–grown
virus, due to the immaturity of the NK cell response (44).
In neonates, the infection with 102 PFU causes a high per-
centage of mortality and runting in survivors. The attenuat-
ing effect of the m152 gene deletion resulted in a higher
number of survivors and an earlier cessation of runting.
The third requirement was also fulfilled: loss of the pheno-
typic difference between deletion mutant and revertant vi-
rus in the absence of the host immune function affected by
the viral gene product. gp40 blocks the export of nascent
MHC class I molecules already loaded with viral peptides.
The predictable consequence is the inhibition of CD8 T cell
priming and CD8 T cell effector function. Loss of the m152
gene should lead to an increased sensitivity of the virus to
lymphocytes. Indeed, the virus mutant grew to smaller titers
in the various tissues tested. This attenuation did reflect a more
stringent control of the deletion mutant by T cell functions,
as elimination of T cells resulted in comparable tissue titers
of mutant and revertant virus. Furthermore, the attenuating
effect of the m152 deletion mutant was absent in C57BL/6
mice that failed to form the functional MHC class I mole-
cules due to the lack of b2-microglobulin expression and
also in mice that have a defect in the maturation of MHC
class I–restricted CD81 T cells due to the deletion of the
CD8 gene. Altogether, this study proves for the first time
that in their natural host, herpesviruses benefit from func-
tions that inhibit antigen presentation in the MHC class I
pathway in vivo.
It remains open whether the observed function is the
only function of the m152 gene product in vivo. MHC class I
molecules activate CD81 T cells and, at the same time, in-
hibit NK cells (45, 46). Accordingly, a prediction of the
transport block of MHC class I molecules due to m152 gene
expression is the susceptibility of MCMV-infected cells for
NK cell–mediated destruction in vivo. A deletion of the
m152 gene and the restoration of MHC class I molecule
transport should result in an enhanced resistance of infected
cells to NK cell control in vivo. Our data do not support
this assumption. Preliminary studies suggest that the lack of
the m152 gene certainly does not make the virus more re-
sistant to control by NK cells (Krmpotic, A., B. Polic,
and S. Jonjic, unpublished data). Both HCMV and MCMV
genes code for glycoproteins that show homology to MHC
class I molecules, UL18 in HCMV (47) and m144 in
MCMV (27, 48). It has been hypothesized that these viral
MHC class I homologues are capable of engaging NK cell
inhibitory receptors to protect cells from lysis due to the
downregulation of MHC class I expression. Attenuation of
MCMV harboring a deletion in the m144 gene has been
explained by enhanced control by NK cells in vivo (48).
However, a more recent study on UL18 functions failed to
confirm the inhibitory function of viral MHC class I homo-
logues on NK cells (49). Therefore, the potential interaction
of m152 with m144 needs to be addressed.
Another explanation is that the remaining functions of
the genes m04 and m06 fully complement the expected NK
cell effect of m152. The genes m04 and m06 have an effect
on MHC class I molecules. Both genes are expressed later
than m152 during the MCMV replication cycle, and both1293 Krmpotic et al.
genes encode glycoproteins that bind tightly to MHC class I
molecules. gp34, encoded by the m04 gene, forms a com-
plex with MHC class I molecules that can be detected on the
surfaces of infected cells, but the functional consequence is
not clear (17). The m06 gene product gp48 binds to MHC
class I molecules in the ER and reroutes them to lysosomes
for rapid proteolytic degradation (18). This leads to the
downregulation of MHC class I surface expression in the late
phase of the replication cycle (18, 23). Here, we show that
the m04 and m06 genes cannot fully compensate all aspects
of the loss of the m152 function. Thus, the interaction be-
tween the m152 gene product and other viral gene functions
is not yet clear and remains to be tested. We are in the pro-
cess of constructing double and triple deletion mutants to
determine the individual contribution of each of the MHC
class I–reactive genes and MHC class I homologues in im-
mune evasion. To this end, we have recently pioneered the
cloning of infectious herpesvirus genomes and have devel-
oped targeted and random mutagenesis techniques (50, 51).
Our results show for the first time that genes that inhibit
antigen presentation in the MHC class I pathway provide a
significant growth advantage for CMV during primary in-
fection. What is the potential benefit for the virus? The con-
ditions of primary infection define the load of latent viral
genomes and the risk of recurrence of the CMV infection
(39). Accordingly, we predict that the m152 gene allows a
higher number of MCMV genomes to establish a latent in-
fection, thereby enhancing the chance for reactivation and
transmission to the next host and thus escaping extinction.
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